Laurence Depoorter1, Liza Sels1, Mieke Deschodt2,3, Bastiaan Van Grootven4,5, Lorenz Van der Linden6,7, Jos Tournoy8,9. 1. Geriatric Department, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. 2. Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven-University of Leuven, Herestraat 49, 3000, Leuven, Belgium. 3. Nursing Science, Department of Public Health, University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland. 4. Research Foundation Flanders, Brussels, Belgium. 5. Department of Public Health and Primary Care, KU Leuven-University of Leuven, Leuven, Belgium. 6. Pharmacy Department, University Hospitals Leuven, Leuven, Belgium. 7. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. 8. Geriatric Department, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. Jos.tournoy@uzleuven.be. 9. Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven-University of Leuven, Herestraat 49, 3000, Leuven, Belgium. Jos.tournoy@uzleuven.be.
Abstract
BACKGROUND AND OBJECTIVES: Atrial fibrillation (AF) is highly prevalent in older adults and has been associated with increased morbidity and mortality. To reduce this AF-related morbidity in older adults, antiarrhythmic drugs (AADs) are regularly used for rhythm control, assuming that increasing time in sinus rhythm reduces AF-related morbidity. However, whether AADs can improve clinical outcomes in older adults remains unclear because of the increased risk for adverse drug events compared with rate control. The aim of this study was to determine the impact of rhythm control versus rate control on clinical outcomes in older adults with AF. DESIGN AND METHODS: We conducted a systematic review and meta-analysis targeting patients aged ≥65 years with AF and using drugs to control rate or rhythm. Articles that met the following criteria were included: enrolled older patients (sample mean ≥75 years) with AF, compared pharmacological rate versus rhythm control, and reported all-cause mortality, cardiovascular mortality, or ischemic stroke. RESULTS: Five observational studies were included. In total, 86,926 patients with AF with a mean age ranging from 75 to 92 years were studied. No differences were found between rhythm and rate control for all-cause mortality (odds ratio [OR] 1.11; 95% confidence interval [CI] 0.78-1.59; I2 = 79.6%; n = 28,526; four studies) and cardiovascular mortality (OR 1.09; 95% CI 0.81-1.47; I2 = 0%; n = 2292; two studies). Rhythm control resulted in fewer strokes (OR 0.86; 95% CI 0.80-0.93; I2 = 0%; n = 59,496), although this was mainly determined by one study. CONCLUSION: All collected data were observational, which precluded making strong recommendations. Furthermore, all CIs were wide, increasing the uncertainty of the observed effects. As such, evidence was insufficient to recommend rhythm or rate control as the first-line therapy for AF in older adults. As AF is particularly prevalent in older people, more randomized controlled trials are needed in this population.
BACKGROUND AND OBJECTIVES:Atrial fibrillation (AF) is highly prevalent in older adults and has been associated with increased morbidity and mortality. To reduce this AF-related morbidity in older adults, antiarrhythmic drugs (AADs) are regularly used for rhythm control, assuming that increasing time in sinus rhythm reduces AF-related morbidity. However, whether AADs can improve clinical outcomes in older adults remains unclear because of the increased risk for adverse drug events compared with rate control. The aim of this study was to determine the impact of rhythm control versus rate control on clinical outcomes in older adults with AF. DESIGN AND METHODS: We conducted a systematic review and meta-analysis targeting patients aged ≥65 years with AF and using drugs to control rate or rhythm. Articles that met the following criteria were included: enrolled older patients (sample mean ≥75 years) with AF, compared pharmacological rate versus rhythm control, and reported all-cause mortality, cardiovascular mortality, or ischemic stroke. RESULTS: Five observational studies were included. In total, 86,926 patients with AF with a mean age ranging from 75 to 92 years were studied. No differences were found between rhythm and rate control for all-cause mortality (odds ratio [OR] 1.11; 95% confidence interval [CI] 0.78-1.59; I2 = 79.6%; n = 28,526; four studies) and cardiovascular mortality (OR 1.09; 95% CI 0.81-1.47; I2 = 0%; n = 2292; two studies). Rhythm control resulted in fewer strokes (OR 0.86; 95% CI 0.80-0.93; I2 = 0%; n = 59,496), although this was mainly determined by one study. CONCLUSION: All collected data were observational, which precluded making strong recommendations. Furthermore, all CIs were wide, increasing the uncertainty of the observed effects. As such, evidence was insufficient to recommend rhythm or rate control as the first-line therapy for AF in older adults. As AF is particularly prevalent in older people, more randomized controlled trials are needed in this population.
Authors: Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns Journal: N Engl J Med Date: 2002-12-05 Impact factor: 91.245
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: Circulation Date: 2014-03-28 Impact factor: 29.690
Authors: Amit Noheria; Peter Shrader; Jonathan P Piccini; Gregg C Fonarow; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; Peter A Noseworthy; James A Reiffel; Benjamin A Steinberg; Laine E Thomas; Eric D Peterson; Bernard J Gersh Journal: JACC Clin Electrophysiol Date: 2015-11-26
Authors: Naqash J Sethi; Joshua Feinberg; Emil E Nielsen; Sanam Safi; Christian Gluud; Janus C Jakobsen Journal: PLoS One Date: 2017-10-26 Impact factor: 3.240
Authors: John Stacy; Rachel Kim; Christopher Barrett; Balaviknesh Sekar; Steven Simon; Farnoush Banaei-Kashani; Michael A Rosenberg Journal: JMIR Form Res Date: 2022-08-11